PARIS, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Curium, the world’s starring atomic medicine company, announced contiguous that with the palmy restarting of the BR2 probe reactor successful Belgium connected 20 December, Curium’s proviso of molybdenum-99 (Mo-99) and iodine-131 is continuing arsenic usual. This follows a shortage of Mo-99 that the full planetary atomic medicine manufacture experienced successful November of this year.
Ciril Faia, Curium CEO SPECT Europe commented: “Curium is committed to ensuring that its operations instrumentality to mean arsenic rapidly arsenic possible, and we are pleased not lone with being capable to again supply a reliable proviso of Mo-99 that our customers person historically enjoyed from Curium, but besides that the hazard of further shortages has been eliminated. A reliable proviso of Mo-99 is critically important for the 40 cardinal patients each twelvemonth astir the satellite who acquisition SPECT scans to diagnose life-critical diseases. With the outlook of the planetary reactors’ schedules akin to that of erstwhile years, for 2023 we foresee nary further proviso concatenation challenges.”
Despite the caller planetary shortage of Mo-99, with an manufacture proviso concatenation track-record that has proven to beryllium resilient implicit the past 10 years, Curium is committed to ensuring that its operations stay steadily reliable done monolithic investments truthful it tin service its 14 cardinal patients annually.
For much information:
Ross Bethell
VP, Head of Global Communications
communications@curiumpharma.com
English (US)